{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:21:11Z","timestamp":1792513271039,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejca.2021.12.029","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T12:20:52Z","timestamp":1643718052000},"page":"1-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5285-1702","authenticated-orcid":false,"given":"Erica","family":"Brivio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auke","family":"Beishuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bourquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8653-1069","authenticated-orcid":false,"given":"Patrick A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Anders","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Maude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3342-0047","authenticated-orcid":false,"given":"Francis J.","family":"Mussai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Vormoor-B\u00fcrger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Vormoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"von Stackelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.ejca.2021.12.029_bib1","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2014.59.5827","article-title":"Non-hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and Challenges ahead","volume":"33","author":"Minard-Colin","year":"2015","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.ejca.2021.12.029_bib2","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","article-title":"Collaborative efforts driving progress in pediatric acute myeloid leukemia","volume":"33","author":"Zwaan","year":"2015","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.ejca.2021.12.029_bib3","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.12.029_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2021.12.029_bib5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2141.2008.07499.x","article-title":"Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria \u2013 a population-based report of the Austrian Berlin-Frankfurt-M\u00fcnster (BFM) Study Group","volume":"144","author":"Reism\u00fcller","year":"2009","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.ejca.2021.12.029_bib6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/leu.2013.106","article-title":"Novel therapies for children with acute myeloid leukaemia","volume":"27","author":"Moore","year":"2013","journal-title":"Leukemia"},{"issue":"28","key":"10.1016\/j.ejca.2021.12.029_bib7","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children's oncology group study","volume":"35","author":"Mosse","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2021.12.029_bib8","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol"},{"issue":"30","key":"10.1016\/j.ejca.2021.12.029_bib9","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1200\/JCO.2008.20.1764","article-title":"Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology","volume":"27","author":"Brugieres","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9757","key":"10.1016\/j.ejca.2021.12.029_bib10","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"},{"issue":"10112","key":"10.1016\/j.ejca.2021.12.029_bib11","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0140-6736(17)31610-0","article-title":"The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE)","volume":"390","author":"Bhakta","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejca.2021.12.029_bib12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1586\/ehm.11.39","article-title":"Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up","volume":"4","author":"Bhatia","year":"2011","journal-title":"Expet Rev Hematol"},{"issue":"3","key":"10.1016\/j.ejca.2021.12.029_bib13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/jnci\/djz207","article-title":"Pediatric trials for cancer therapies with targets potentially relevant to pediatric cancers","volume":"112","author":"Hwang","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ejca.2021.12.029_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1470-2045(18)30105-0","article-title":"10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers","volume":"19","author":"Pearson","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.12.029_bib15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2019.12.029","article-title":"ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients","volume":"127","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.12.029_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2019.01.013","article-title":"ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children","volume":"110","author":"Pearson","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2021.12.029_bib17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/bjh.14310","article-title":"CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy","volume":"180","author":"Bras","year":"2018","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.ejca.2021.12.029_bib18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.ejca.2021.12.029_bib19","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2021.12.029_bib20","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2021-150272","article-title":"Isatuximab in combination with chemotherapy in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia or acute myeloid leukemia (ISAKIDS): interim analysis","volume":"138","author":"Baruchel","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ejca.2021.12.029_bib21","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2021.12.029_bib22","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2021.12.029_bib23","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood-2006-04-016709","article-title":"Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia","volume":"108","author":"Jeha","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejca.2021.12.029_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.20.01564","article-title":"Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell\u2013redirected bispecific antibodies","volume":"39","author":"Lussana","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2021.12.029_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-020-00342-x","article-title":"Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study","volume":"10","author":"Locatelli","year":"2020","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.ejca.2021.12.029_bib26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ejca.2021.12.029_bib27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2021.12.029_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2018-99-111845","article-title":"Blinatumomab in combination with immune checkpoint inhibitors of PD-1 and CTLA-4 in adult patients with relapsed\/refractory (R\/R) CD19 positive B-cell acute lymphoblastic leukemia (ALL): preliminary results of a phase I study","volume":"132","author":"Webster","year":"2018","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.ejca.2021.12.029_bib29","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 Year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2021.12.029_bib30","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1182\/blood-2021-148967","article-title":"Blinatumomab associated seizure risk in patients with Down syndrome and B-lymphoblastic leukemia: an interim report from children's oncology group (COG) study AALL1731","volume":"138","author":"Li","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ejca.2021.12.029_bib31","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","article-title":"High levels of CD34+CD38low\/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study","volume":"96","author":"Vergez","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ejca.2021.12.029_bib32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cyto.b.21745","article-title":"CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping","volume":"96","author":"Bras","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"issue":"6","key":"10.1016\/j.ejca.2021.12.029_bib33","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejca.2021.12.029_bib34","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1038\/leu.2014.128","article-title":"Targeting of acute myeloid leukemia in\u00a0vitro and in\u00a0vivo with an anti-CD123 mAb engineered for optimal ADCC","volume":"28","author":"Busfield","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.ejca.2021.12.029_bib35","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.ejca.2021.12.029_bib36","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2021.12.029_bib37","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.ejca.2021.12.029_bib38","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1182\/blood.2020007848","article-title":"A Phase I study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study)","volume":"137","author":"Brivio","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2021.12.029_bib39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-134774","article-title":"A phase II study of single-agent inotuzumab ozogamicin in pediatric CD22-positive relapsed\/refractory acute lymphoblastic leukemia: results of the ITCC-059 study","volume":"136","author":"Brivio","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.12.029_bib40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood-2019-128977","article-title":"A phase 2 trial of inotuzumab ozogamicin (InO) in children and young adults with relapsed or refractory (R\/R) CD22+ B-acute lymphoblastic leukemia (B-all): results from children's oncology group protocol AALL1621","volume":"134","author":"O'Brien","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2021.12.029_bib41","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/bjh.17333","article-title":"Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series","volume":"193","author":"Brivio","year":"2021","journal-title":"Br J Haematol"},{"issue":"Supplement_1","key":"10.1016\/j.ejca.2021.12.029_bib42","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2019-128648","article-title":"Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.12.029_bib43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2020.04.038","article-title":"Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"136","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.12.029_bib44","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2016.34.15_suppl.2509","article-title":"Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR)","volume":"34","author":"B","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.ejca.2021.12.029_bib45","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2019-123794","article-title":"In\u00a0vivo evaluation of mesothelin as a therapeutic target in pediatric acute myeloid leukemia","volume":"134","author":"Gopalakrishnapillai","year":"2019","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ejca.2021.12.029_bib46","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.2020009806","article-title":"Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ALCL: results of COG trial ANHL12P1","volume":"137","author":"Lowe","year":"2021","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.ejca.2021.12.029_bib47","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2021.12.029_bib48","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1158\/1078-0432.CCR-08-1123","article-title":"Structural and functional alterations of FLT3 in acute myeloid leukemia","volume":"15","author":"Meshinchi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2021.12.029_bib49","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2021.12.029_bib50","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjh.15593","article-title":"A phase 1\/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia","volume":"185","author":"Zwaan","year":"2019","journal-title":"Br J Haematol"},{"issue":"Supplement_1","key":"10.1016\/j.ejca.2021.12.029_bib51","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/blood-2019-129557","article-title":"Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3\/ITD+ AML improves event-free survival and reduces relapse risk: a report from the children's oncology group protocol AAML1031","volume":"134","author":"Pollard","year":"2019","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ejca.2021.12.029_bib52","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2021.12.029_bib53","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ejca.2021.12.029_bib54","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-1998","article-title":"A phase I study of quizartinib combined with chemotherapy in relapsed childhood leukemia: a therapeutic advances in childhood leukemia & lymphoma (TACL) study","volume":"22","author":"Cooper","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2021.12.029_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112493","article-title":"Molecular mechanisms of resistance to FLT3 inhibitors in acute myeloid leukemia: ongoing Challenges and future treatments","volume":"9","author":"Scholl","year":"2020","journal-title":"Cells"},{"issue":"18","key":"10.1016\/j.ejca.2021.12.029_bib56","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.12.029_bib57","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2021.08.022","article-title":"Second paediatric strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European medicines agency with the participation\u00a0of the food and drug administration","volume":"157","author":"Pearson","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2021.12.029_bib58","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41379-019-0336-3","article-title":"PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma","volume":"33","author":"Shen","year":"2020","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.ejca.2021.12.029_bib59","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S1470-2045(21)00536-2","article-title":"Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study","volume":"22","author":"Fischer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.12.029_bib60","doi-asserted-by":"crossref","first-page":"10505","DOI":"10.1200\/JCO.2020.38.15_suppl.10505","article-title":"Final analysis of phase I study of ceritinib in pediatric\u00a0patients with malignancies harboring activated anaplastic lymphoma kinase (ALK)","volume":"38","author":"Schulte","year":"2020","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.ejca.2021.12.029_bib61","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.20.00505","article-title":"Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial","volume":"38","author":"Camidge","year":"2020","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2021.12.029_bib62","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ejca.2021.12.029_bib63","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejca.2021.12.029_bib64","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.12.029_bib65","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.05.020","article-title":"Ponatinib in childhood Philadelphia chromosome-positive leukaemias: an international registry of childhood chronic myeloid leukaemia study","volume":"136","author":"Millot","year":"2020","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2021.12.029_bib66","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.16338","article-title":"Experience with ponatinib in paediatric patients with leukaemia","volume":"189","author":"Rossoff","year":"2020","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.ejca.2021.12.029_bib67","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2014-04-531871","article-title":"Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition","volume":"124","author":"Irving","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ejca.2021.12.029_bib68","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1038\/s41375-021-01291-5","article-title":"MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance","volume":"35","author":"van der Zwet","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.ejca.2021.12.029_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002200","article-title":"IL-7 receptor mutations and steroid resistance in pediatric T cell acute lymphoblastic leukemia: a genome sequencing study","volume":"13","author":"Li","year":"2016","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.ejca.2021.12.029_bib70","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.3324\/haematol.2017.174060","article-title":"Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in\u00a0vivo","volume":"103","author":"Kerstjens","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ejca.2021.12.029_bib71","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1512455","article-title":"Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model","volume":"8","author":"Chu","year":"2019","journal-title":"OncoImmunology"},{"issue":"S3","key":"10.1016\/j.ejca.2021.12.029_bib72","article-title":"Ibrutinib+rice\/rvici for r\/r mature b-nhl in children\/young adults: sparkle trial interim analysis","volume":"68","author":"Burke","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2021.12.029_bib73","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2018-99-110221","article-title":"A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (INCB18424-269\/AALL1521): dose-finding results from the Part 1 safety phase","volume":"132","author":"Tasian","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2021.12.029_bib74","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-15-2869","article-title":"Synergistic drug combinations with a CDK4\/6 inhibitor in T-cell acute lymphoblastic leukemia","volume":"23","author":"Pikman","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2021.12.029_bib75","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-16-2898","article-title":"A phase I study of the CDK4\/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors","volume":"23","author":"Geoerger","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.12.029_bib76","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/JBM.S70716","article-title":"IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives","volume":"7","author":"Mondesir","year":"2016","journal-title":"J Blood Med"},{"issue":"6","key":"10.1016\/j.ejca.2021.12.029_bib77","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejca.2021.12.029_bib78","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.ejca.2021.12.029_bib79","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group","volume":"105","author":"Richard","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ejca.2021.12.029_bib80","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","article-title":"Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study","volume":"120","author":"Messinger","year":"2012","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.ejca.2021.12.029_bib81","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1182\/blood-2019-127350","article-title":"Phase 1b study of carfilzomib in combination with induction chemotherapy in children with relapsed or refractory acute lymphoblastic leukemia (ALL)","volume":"134","author":"Burke","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.ejca.2021.12.029_bib82","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1182\/blood-2019-129805","article-title":"Safety, efficacy, and PK of the BCL2 inhibitor venetoclax in combination with chemotherapy in pediatric and young adult patients with relapsed\/refractory acute myeloid leukemia and acute lymphoblastic leukemia: phase 1 study","volume":"134","author":"Karol","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2021.12.029_bib83","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.12.029_bib84","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy","volume":"32","author":"Pan","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2021.12.029_bib85","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.813.813","article-title":"Preliminary results from a phase ib study evaluating BCL-2 inhibitor venetoclax in combination with MEK inhibitor cobimetinib or MDM2 inhibitor idasanutlin in patients with relapsed or refractory (R\/R) AML","volume":"130","author":"Daver","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2021.12.029_bib86","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"issue":"22","key":"10.1016\/j.ejca.2021.12.029_bib87","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V128.22.2780.2780","article-title":"Final report of phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in children with relapsed or refractory MLL-r acute leukemia","volume":"128","author":"Shukla","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2021.12.029_bib88","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2021.12.029_bib89","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2021-146944","article-title":"Safety and efficacy of menin inhibition in patients (pts) with MLL-rearranged and NPM1 mutant acute leukemia: a phase (Ph) 1, first-in-human study of SNDX-5613 (AUGMENT 101)","volume":"138","author":"Stein","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2021.12.029_bib90","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/leu.2016.327","article-title":"Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia","volume":"31","author":"Dafflon","year":"2017","journal-title":"Leukemia"},{"issue":"38","key":"10.1016\/j.ejca.2021.12.029_bib91","doi-asserted-by":"crossref","first-page":"63506","DOI":"10.18632\/oncotarget.18843","article-title":"Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies","volume":"8","author":"Vardon","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ejca.2021.12.029_bib92","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s10637-021-01149-8","article-title":"Safety, PK\/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors","volume":"39","author":"Cheng","year":"2021","journal-title":"Invest New Drugs"},{"issue":"12","key":"10.1016\/j.ejca.2021.12.029_bib93","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","article-title":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","volume":"26","author":"Burd","year":"2020","journal-title":"Nat Med"},{"issue":"36","key":"10.1016\/j.ejca.2021.12.029_bib94","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1200\/JCO.20.02152","article-title":"Accelerating the global development of pediatric cancer drugs: a call to coordinate the submissions of pediatric investigation plans and pediatric study plans to the European medicines agency and US food and drug administration","volume":"38","author":"Reaman","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.12.029_bib95","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/s41375-020-0749-5","article-title":"Ibrutinib plus CIT for R\/R\u00a0mature B-NHL in children (SPARKLE trial): initial safety,\u00a0pharmacokinetics, and efficacy","volume":"34","author":"Burke","year":"2020","journal-title":"Leukemia"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921013174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921013174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:34:32Z","timestamp":1760733272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921013174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":95,"alternative-id":["S0959804921013174"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.029","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}